<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is relatively common, with an incidence estimated as high as 50 cases per 100,000 people per year </plain></SENT>
<SENT sid="1" pm="."><plain>This <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mainly affects older (&gt;or=60 years) patients </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> refers to a collection of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> that share an ineffective production, or hematopoiesis, of <z:mpath ids='MPATH_458'>normal</z:mpath> bone marrow or myeloid cells </plain></SENT>
<SENT sid="3" pm="."><plain>As progressive <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> occurs, patients generally display gradually worsening cytopenias specific to the type of bone marrow cell affected, such as <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> or <z:hpo ids='HP_0001875'>neutropenia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients often develop disease-related <z:hpo ids='HP_0001903'>anemia</z:hpo> requiring <z:hpo ids='HP_0011010'>chronic</z:hpo> blood transfusion; this can lead to complications including <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>As <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> progresses and the number of bone marrow blasts increases, the disease transforms into <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="6" pm="."><plain>Several classification systems have been developed to identify and differentiate particular types of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Proper identification is essential, allowing the oncologist to determine prognosis, as well as the optimal therapeutic strategy </plain></SENT>
<SENT sid="8" pm="."><plain>Several agents have been developed or are under investigation for the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, with the therapeutic goal of increasing survival and decreasing the rate of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> transformation </plain></SENT>
<SENT sid="9" pm="."><plain>Currently, 3 agents are FDA-approved: <z:chebi fb="0" ids="2038">azacitidine</z:chebi>, <z:chebi fb="0" ids="50131">decitabine</z:chebi>, and lenalidomide </plain></SENT>
<SENT sid="10" pm="."><plain>This clinical roundtable will discuss the optimal management of patients with each of these approved therapies, as well as the various classification systems used to differentiate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> subtypes for treatment </plain></SENT>
</text></document>